Valneva Reports P-II Trials Data of Tetravalent Shigella Vaccine S4V2

Shots: Valneva has reported positive results from 2 P-II trials of S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis: the infant trial (S4V02) in 110 infants aged 9mos. in Kenya & the controlled human infection model (CHIM) trial (S4V03) in ~120 healthy adults in the US In S4V02, S4V2 (2 dose levels; 2-dose schedule) showed significant increases in anti-LPS IgG levels vs control for all 4 targeted Shigella serotypes, with titers above baseline at 6mos.; S4V03 met its 1EP with a significant reduction in S. sonnei shigellosis vs PBO S4V2 showed a favorable safety profile across both trials; Valneva is evaluating full datasets to determine next development steps Ref: Valneva  |   Image: Valneva  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Valneva Reports P-II Trials Data of Tetravalent Shigella Vaccine S4V2 appeared first on PharmaShots.